Previous 10 | Next 10 |
STAMFORD, Conn. and BASEL, Switzerland and BEIJING and CAMBRIDGE, Mass., April 17, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (NASDAQ: SWTX), and BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), today announced that they will present updated clinical data from the Phase 1...
STAMFORD, Conn. and BASEL, Switzerland and BEIJING and CAMBRIDGE, Mass. and SAN MATEO, Calif., April 17, 2023 (GLOBE NEWSWIRE) -- MapKure, LLC, SpringWorks Therapeutics, Inc. (NASDAQ: SWTX), and BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), today announced that they will present up...
MapKure, LLC, BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), and SpringWorks Therapeutics, Inc. (NASDAQ: SWTX), today announced that they will present updated clinical data from the Phase 1a/1b study of BGB-3245, an investigational, selective RAF dimer inhibitor, in adult patients with a...
2023-04-17 07:45:48 ET Summary BeiGene's innovative and diverse product pipeline, including Brukinsa and Tislelizumab, positions the company at the forefront of the oncology space. BeiGene's sound financial health, demonstrated by a robust balance sheet and prudent management, ena...
PD-1 inhibitor tislelizumab under review by Brazil’s National Health Surveillance Agency to treat non-small cell lung cancer and esophageal cancer Future regional expansion planned in Argentina, Mexico, Chile, Colombia, Uruguay, and other countries BeiGene (NASDAQ: BGNE; ...
2023-04-09 12:00:00 ET The largest meeting in the world of cancer research is set to kick off this week. The annual meeting of the American Association for Cancer Research (AACR) is a much sought-after event in the healthcare calendar, with many pharma companies scheduled to highlight their...
2023-04-06 17:24:30 ET Shares of BeiGene (NASDAQ: BGNE) rose 14.3% by late Thursday afternoon and closed the day 12.48% higher. The Chinese biotech company recently signed a collaboration deal with Israel biotech company Enlivex Therapeutics to evaluate the safety and efficacy o...
BeiGene, Ltd. (NASDAQ: BGNE) has caught the attention of the investment community today with its bullish price action. The company's shares are currently up 9.06% on the day to $231.2. BeiGene, Ltd. discovers, develops, manufactures, and commercializes medicines for cancer therapeutics in the ...
2023-04-04 22:01:45 ET Summary Baker Brothers’ 13F portfolio value increased from $15.27B to $16.65B this quarter. Replimune Group stake was substantially increased this quarter. The top three positions are Seagen, Incyte Corporation, and BeiGene, and they add up to alm...
Pryor will spearhead BeiGene’s efforts to pair global health equity with diversity and inclusion BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced the appointment of Julius Pryor III as its first Global Head of Diversity and Health ...
News, Short Squeeze, Breakout and More Instantly...
$800 million investment in New Jersey supports global growth and expansion with technologically advanced manufacturing capacity and clinical development capabilities for novel cancer medicines BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today ann...
2024-07-20 02:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
BeiGene , Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced the appointment of Aaron Rosenberg as Chief Financial Officer, effective July 22. Mr. Rosenberg will succeed Julia Wang, who is departing to pursue external opportunities and will stay with the C...